Drug Profile
BIIA 0388
Alternative Names: BIIA388C1Latest Information Update: 17 Oct 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Neuroprotectants
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cerebral ischaemia; Epilepsy
Most Recent Events
- 17 Oct 2022 Chemical structure information added
- 14 Jun 2001 No-Development-Reported for Cerebral ischaemia in Germany (Unknown route)
- 14 Jun 2001 No-Development-Reported for Epilepsy in Germany (Unknown route)